A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
This study is testing an investigational targeted cancer treatment called neladalkib, or NVL-655, for people with advanced cancers. Researchers want to find the safest dose and see how well it works against tumors that have a specific genetic change called an ALK mutation.
Adults 18 and older with advanced non-small cell lung cancer or other solid tumors involving a confirmed ALK gene change may be able to join. Participants must not be on other active cancer treatments and should not have major recent surgeries.
Participants will receive the study medicine and have their health closely monitored to check for safety and how well the treatment shrinks tumors. Some patients may also take part in a sub-study looking at how the drug interacts with other common medications.
The study is currently active and recruiting patients at medical centers in locations such as Orange, Sacramento, and Stanford, California.
- 1Tests a new targeted medicine called neladalkib for advanced ALK-positive cancers.
- 2Open to adults with advanced non-small cell lung cancer and other solid tumors.
- 3Currently recruiting participants at multiple locations in California.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.